(Total Views: 309)
Posted On: 05/17/2019 11:30:03 AM
Post# of 153986
I agree with your opinion as being the most plausible also Misiu.
I am mostly wondering though why non-CCR5delta BMT cannot cure patients with on HAART with undetectable viral load, but they think leronlimab may be able to do so .
Again maybe leronlimab is not only safer but also more potent against CCR5 HIV through its mechanism of action and longer half-life (10 days versus 1-2?) like your said which thereby subdues the active HIV hidden reservoirs more effectively.
I am mostly wondering though why non-CCR5delta BMT cannot cure patients with on HAART with undetectable viral load, but they think leronlimab may be able to do so .
Again maybe leronlimab is not only safer but also more potent against CCR5 HIV through its mechanism of action and longer half-life (10 days versus 1-2?) like your said which thereby subdues the active HIV hidden reservoirs more effectively.
(0)
(0)
